KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Equity Average (2018 - 2025)

Esperion Therapeutics' Equity Average history spans 8 years, with the latest figure at -$376.7 million for Q4 2025.

  • For Q4 2025, Equity Average rose 0.74% year-over-year to -$376.7 million; the TTM value through Dec 2025 reached -$376.7 million, up 0.74%, while the annual FY2025 figure was -$345.3 million, 18.14% up from the prior year.
  • Equity Average reached -$376.7 million in Q4 2025 per ESPR's latest filing, up from -$442.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$182.8 million in Q1 2021 to a low of -$442.4 million in Q3 2025.
  • Average Equity Average over 5 years is -$338.3 million, with a median of -$342.2 million recorded in 2021.
  • Peak YoY movement for Equity Average: tumbled 1727.85% in 2021, then rose 12.26% in 2024.
  • A 5-year view of Equity Average shows it stood at -$279.8 million in 2021, then dropped by 10.4% to -$308.9 million in 2022, then plummeted by 39.99% to -$432.5 million in 2023, then rose by 12.26% to -$379.5 million in 2024, then rose by 0.74% to -$376.7 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Equity Average are -$376.7 million (Q4 2025), -$442.4 million (Q3 2025), and -$429.9 million (Q2 2025).